RecruitingPhase 3NCT06291207

A Study to Evaluate the Efficacy and Safety of AD-224

A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension

Sponsor

Addpharma Inc.

Enrollment

252 participants

Start Date

Apr 15, 2024

Study Type

INTERVENTIONAL

Conditions

Hypertension,Essential

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-224

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating the effectiveness and safety of a medication called AD-224 for people with high blood pressure (essential hypertension — meaning high blood pressure not caused by another medical condition). **You may be eligible if...** - You have been diagnosed with essential (primary) high blood pressure - You meet additional specific criteria outlined by the study team **You may NOT be eligible if...** - Your high blood pressure is caused by another underlying medical condition (secondary hypertension) - You do not meet other study-specific criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.